Kolon Investigative Site : CenExel JBR
Salt Lake City, Utah, 84107, United States
NCT Number: NCT04238793
Escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 1 / Phase 2
Salt Lake City, Utah, 84107, United States
This is a first-in-human (FIH), multicenter, double-blind, placebo-controlled, parallel-group, escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031 administered by transforaminal epidural injection to subjects aged 18 to 75 years with neuropathic pain due to LSR.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
To participate in the study, subjects must have met the following criteria at Visit 1 (Screening,
Day -56 to Day -15):
Informed consent must have been obtained before any screening activities are conducted.
Exclusion criteria
Subjects were excluded from the study if 1 or more of the following criteria were applicable:
KLS-2031 administered by transforaminal epidural injection
Normal Saline (0.9%) administered by transforaminal epidural injection
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52
Frequency and nature of AEs, laboratory test results, vital sign measurements, physical and complete neurological examinations, and 12-lead electrocardiograms (ECGs)
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 78, Week 104
Frequency and nature of AEs, laboratory test results, vital sign measurements, physical and complete neurological examinations, and 12-lead ECGs
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52
The occurrence of injection site reactions
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
calculated as the average of the subject's last 4 available PI-NRS daily scores in the week before the study visit
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Time frame: Week 12, Week 26, Week 52, Week 104
based on the Patient Global Impression of Change (PGIC)
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52
, defined as the day and time a subject starts pain medication other than acetaminophen for the treatment of neuropathic pain
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Time frame: Week 12, Week 26, Week 52, Week 104
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52
using the Columbia Suicide Severity Rating Scale (C-SSRS)
Kolon Life Science
Industry
A Phase 1/2a, First-in-Human, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Therapeutic Activity of Single Ascending Doses of KLS-2031 Administered by Transforaminal Epidural Injection in Patients With Neuropathic Pain From Lumbosacral Radiculopathy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.